Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,003 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platelets Clear all
Terminated Phase 1 Interventional

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

NCT01561950
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
eptacog alfa (activated), clopidogrel, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction

NCT00938340
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Walnut "meat", Walnut Oil, Walnut Skins, Whole walnut
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 28, 2026, 6:14 AM EDT
Not yet recruiting Early Phase 1 Interventional

Radiographic Changes in the Maxillary Sinus Following Closed Sinus Augmentation With Leukocyte Platelet Rich Fibrin

NCT07836725
View directory record Official record
Conditions
Partially Edentulous Maxilla
Interventions
Leukocyte Platelet Rich Fibrin
Biological
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Cold-stored Platelet Early Intervention in TBI

NCT04726410
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Cold Stored Platelets, Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 28, 2026, 6:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Measurement of Platelet Dense Granule Release in Healthy Volunteers

NCT00942617
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Aspirin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas

NCT01140568
View directory record Official record
Conditions
Glioma
Interventions
nilotinib
Drug
Lead sponsor
David Piccioni, M.D., Ph.D
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

GM03 - Platelet RNA Signatures of Aspirin

NCT05278637
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 28, 2026, 6:14 AM EDT
Terminated Not applicable Interventional

Single Blinded First CMC Osteoarthritis Treatment

NCT03196310
View directory record Official record
Conditions
Osteoarthritis Thumb
Interventions
Platelet Concentrate, Corticosteroid injection, Normal Saline
Drug · Other
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 28, 2026, 6:14 AM EDT
Completed No phase listed Observational

Platelets as Regulators of Inflammation in Cardiac Surgery

NCT02568410
View directory record Official record
Conditions
Systemic Inflammatory Response Syndrome, Acute Kidney Injury
Interventions
coronary artery bypass grafting using cardiopulmonary bypass
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 28, 2026, 6:14 AM EDT
Completed No phase listed Observational

Platelet-rich Plasma for Thumb Carpometacarpal Joint Osteoarthritis

NCT04886349
View directory record Official record
Conditions
Thumb Carpometacarpal Joint Osteoarthritis
Interventions
Platelet-rich plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 28, 2026, 6:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds

NCT02307448
View directory record Official record
Conditions
Foot Ulcer Chronic, Skin Ulcer Venous Stasis Chronic, Pressure Ulcer
Interventions
Platelet Rich Plasma, Standard of Care
Procedure
Lead sponsor
ACR Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 28, 2026, 6:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance Evaluation of T-TAS 01 PL Chip

NCT03621020
View directory record Official record
Conditions
Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
Interventions
T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
Diagnostic Test
Lead sponsor
Hikari Dx, Inc.
Other
Eligibility
21 Years and older
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
5
States / cities
San Francisco, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 28, 2026, 6:14 AM EDT
Not listed Not applicable Interventional

A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Non-Healing Diabetic Foot Ulcers

NCT02312596
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
PRP Concepts Fibrin Bio-Matrix, Usual and Customary Practice
Device · Other
Lead sponsor
PRP Concepts, LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of SB 659032 on Platelet Function

NCT01750827
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB659032
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 28, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

NCT05785819
View directory record Official record
Conditions
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Interventions
VLX-1005, Placebo
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 28, 2026, 6:14 AM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172
View directory record Official record
Conditions
Intracranial Arteriosclerosis, Stroke
Interventions
Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
114
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

NCT02907359
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
Guadecitabine, Treatment Choice
Drug · Other
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Duarte, California • Rancho Mirage, California • Fleming Island, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 28, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Zevalin, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Sun City, Arizona • Athens, Georgia • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag

NCT00370331
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435
View directory record Official record
Conditions
Neuroblastoma
Interventions
Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 29 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional

Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

NCT00187109
View directory record Official record
Conditions
Germ Cell Tumors, Hepatic Cancer, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma
Interventions
Recombinant Human Thrombopoietin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2008 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Application of L-PRF in Periodontal Surgery

NCT06296498
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Leukocyte Platelet-rich fibrin, Standard of care OFD
Procedure · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 28, 2026, 6:14 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 28, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT03222609
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 28, 2026, 6:14 AM EDT